Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

The Lancet

Volumn 383, Issue 9936, 2014, Pages 2222-2231

  Clotet, Bonaventura ^a   Feinberg, Judith ^b   Van Lunzen, Jan ^c   Khuong Josses, Marie Aude ^d   Antinori, Andrea ^e   Dumitru, Irina ^f   Pokrovskiy, Vadim ^g   Fehr, Jan ^h   Ortiz, Roberto ⁱ   Saag, Michael ^j   Harris, Julia ^k   Brennan, Clare ^l   Fujiwara, Tamio ^m   Min, Sherene ^l  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d DELAFONTAINE HOSPITAL   (France)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f Infectious Diseases Hospital   (Romania)

^g CENTRAL RESEARCH INSTITUTE OF EPIDEMIOLOGY   (Russian Federation)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ ORLANDO IMMUNOLOGY CENTER   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k GLAXOSMITHKLINE   (United Kingdom)

^l GLAXOSMITHKLINE   (United States)

^m SHIONOGI AND CO LTD   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DARUNAVIR; DOLUTEGRAVIR; LOW DENSITY LIPOPROTEIN; RITONAVIR; VIRUS RNA; ABACAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LAMIVUDINE; TENOFOVIR;

ADULT; AGED; ANUS FISTULA; ARTHRALGIA; ARTICLE; ASTHMA; BACKACHE; BACTERIAL PNEUMONIA; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CONGESTIVE CARDIOMYOPATHY; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; FAINTNESS; FATIGUE; FEMALE; FEVER; FOLLOW UP; GRAND MAL EPILEPSY; HEADACHE; HEART INFARCTION; HEMATEMESIS; HEMORRHOID; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; KIDNEY FAILURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ODYNOPHAGIA; OPEN STUDY; PANCREATITIS; PERITONEUM ADHESION; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; POLYARTHRITIS; POSTOPERATIVE ILEUS; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; SKIN ABSCESS; STAPHYLOCOCCUS INFECTION; SUICIDE ATTEMPT; TONSILLITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS LOAD; VOMITING; ABDOMINAL ABSCESS; ACUTE HEPATITIS; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ACUTE SINUSITIS; ADULT DISEASE; APPENDICITIS; DRUG ABUSE; DRUG INDUCED HEADACHE; EPILEPSY; HEPATITIS C; HERPES ZOSTER; OUTCOME ASSESSMENT; PERINEAL ABSCESS; PNEUMONIA; RASH; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; STAB WOUND; UROLITHIASIS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RITONAVIR; SERUM ALBUMIN; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903303497     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60084-2     Document Type: Article

References (34)

1. Clumeck N, Pozniak A, RaffiF, and the EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71.
2. Hammer SM, Eron JJ Jr., Reiss P, et al, and the International AIDS Society-USA. Antiretroviral treatment of adult HIV infection : 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
3. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidel ines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed Oct 24, 2013).
4. Gazzard BG, Anderson J, Babiker A, et al, and the BHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
5. Daar ES, Tierney C, Fischl MA, et al, and the AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-56.
6. Isentress [package insert]. Whitehouse Station, NJ USA: Merck & Co Inc 2011.
7. US Food and Drug Administration. FDA approves new combination pill for HIV trea tment for some patients. 2013. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm317004.htm (accessed Sept 30, 2013).
8. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegra vir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010; 201: 814-22.
9. Schrijvers R, Debyser Z. Quad's in it for antiretroviral therapy? Lancet 2012; 379: 2403-05.
10. Tivicay [package insert]. Research Triangle Park, NC, USA: ViiV Healthcare; 2013.
11. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012; 56: 1627-29.
12. RaffiF, Rachlis A, Stellbrink H-J, et al, and the SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735-43.
13. RaffiF, Jaeger H, Quiros-Roldan E, et al, and the extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013; 13: 927-35.
14. Walmsley SL, Antela A, Clumeck N, et al, and the SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-18.
15. EuroQol Group. EQ-5D. 2013. http://www.euroqol.org (accessed Sept 30, 2013).
16. Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res 2001; 10: 517-31.
17. Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health 2006; 9: 320-33.
18. Justice AC, Holmes W, Giff ord AL, et al, and the Adult AIDS Clinical Trials Unit Outcomes Committee. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001; 54 (suppl 1): S77-90.
19. Hill A, Sabin C. Designing and interpreting HIV noninferiority trials in naive and experienced patients. AIDS 2008; 22: 913-21.
20. Wiens BL, Dmitrienko A. The fallback procedure for evaluating a single family of hypotheses. J Biopharm Stat 2005; 15: 929-42.
21. Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J 2008; 50: 667-77.
22. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97.
23. Norvir [package insert]. North Chicago, IL, USA: AbbVie Inc; 2013.
24. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-21.
25. Prezista [package insert]. Titusville, NJ, USA: Janssen Pharmaceuticals Inc; 2013.
26. Stellbrink H-J, Reynes J, Lazzarin A, et al, and the SPRING-1 Team. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013; 27: 1771-78.
27. van Lunzen J, Ma ggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12: 111-18.
28. Burgess E, Blair A, Krichman K, Cutler RE. Inhibition of renal creatinine secretion by cimetidine in humans. Ren Physiol 1982; 5: 27-30.
29. Kastrup J, Petersen P, Bartram R, Hansen JM. The effect of trimethoprim on serum creatinine. Br J Urol 1985; 57: 265-68.
30. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75: 990-96.
31. Lepist EI, Murray BP, Tong L, Roy A, Bannister R, Ray AS. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and effl ux transporters. 51st Interscience Co nference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Sept 17-20, 2011. Abstract A1-1724.
32. DeJesus E, Rockstroh JK, Henry K, et al, and the GS-236-0103 Study Team. Co-formulated elvi tegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, no n-inferiority trial. Lancet 2012; 379: 2429-38.
33. Sax PE, DeJesus E, Mills A, et al, and the GS-US-236-0102 study team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versu s co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-48.
34. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on integrase inhibitor use in antiretroviral treatment-naive HIV-infected individuals from the HHS panel on antiretroviral guidelines for adults an d adolescents. http://aidsinfo. nih.gov/contentfiles/upload/AdultARV-INSTIRecommendations. pdf (accessed Nov 1, 2013).